Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > BUSINESS
BUSINESS
- IMS Japan VP Miyoshi Calls for Focus Shift from Long-Listed Products to Abolishment of Post-Market Expansion Re-Pricing
February 29, 2012
- Major European, US Drug Makers Turning Sights Toward “Mini-buster” Drugs for Rare Diseases
February 29, 2012
- OTS102 Fails to Prolong Survival in Pancreatic Cancer: OncoTherapy Science
February 29, 2012
- Wakamoto to Comarket Bausch & Lomb’s Ocuvite Series of Eye Supplements from April 1
February 29, 2012
- Sanofi Pasteur Files for Approval for Monovalent IPV
February 27, 2012
- Novartis Pharma Submits Afinitor for Add’l Indication of Tuberous Sclerosis
February 27, 2012
- EMA Accepts MAA for Peginesatide for Treatment of Anemia Associated with CKD: Takeda
February 27, 2012
- JCR Pharmaceuticals Announces Favorable Results from PI/II Trial of Stem-cell-based Therapy
February 27, 2012
- Diabetes Treatments: Their Development and Market (2)
February 27, 2012
- Daiichi Sankyo and Terumo Codevelop Intradermal Vaccine
February 24, 2012
- Nichi-Iko and Pfizer Japan Obtain Approval for Cisplatin Generic for Indication of Biliary Tract Cancer
February 24, 2012
- Ajinomoto Pharm. Files NDA for New Oral Bowel Cleansing Agent in Japan
February 24, 2012
- SymBio’s Licensee InnoPharmax Launches Bendamustine in Taiwan
February 24, 2012
- Eli Lilly Receives Approval for Zyprexa, First for Depression in Bipolar Disorder
February 23, 2012
- Use of Rasilez in Combination with ACE Inhibitors, ARBs in Patients with Diabetes to Be Contraindicated in Europe: Novartis
February 23, 2012
- RaQualia Maintains Focus on Pain, GI Diseases in New Midterm Management Plan
February 23, 2012
- Novo Nordisk President Says “Current Pipeline Most Substantial”
February 22, 2012
- Takeda’s Ulcerative Colitis Treatment Vedolizumab Shows Significant Improvement and Remission in Global PIII Trial
February 22, 2012
- CMIC HD Files NDA for UCD Treatment in Japan
February 22, 2012
- Shionogi, Eli Lilly Japan Announce Add’l Indication of DNP for Cymbalta
February 22, 2012
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…